Eptifibatide adverse reactions

Revision as of 22:23, 5 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Eptifibatide}} {{CMG}}; {{AE}} {{SS}} ==Adverse Reactions== The following serious adverse reaction is also discussed elsewhere in the labeling: Bleeding [see Con...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Eptifibatide
INTEGRILIN® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Eptifibatide
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Adverse Reactions

The following serious adverse reaction is also discussed elsewhere in the labeling:

Bleeding [see Contraindications and Warnings and Precautions ]

[1]


References

  1. "INTEGRILIN (EPTIFIBATIDE) INJECTION, SOLUTION [MERCK SHARP & DOHME CORP.]". Retrieved 5 February 2014.

Template:WikiDoc Sources